Drug Insight: choosing a drug treatment strategy for women with osteoporosis

an evidence-based clinical perspective

Piet P. Geusens, Christian H. Roux, David M. Reid, Willem F. Lems, Silvano Adami, Jonathan D. Adachi, Philip N. Sambrook, Kenneth G. Saag, Nancy E. Lane, Marc C. Hochberg

Research output: Contribution to journalLiterature review

28 Citations (Scopus)

Abstract

Many randomized controlled trials (RCTs) have investigated drug treatment for women at high risk of fracture, with a reduction in fracture risk as their end point. There has also been progress in identifying women at the highest risk of fractures. The most important clinical determinant contributing to the clinical decision of initiating and choosing drug therapy for fracture prevention is a woman's fracture risk, which, in RCTs, was determined by menopausal state, age, bone mineral density, fracture history, fall risks and glucocorticoid use. Women with secondary osteoporosis were excluded, except in studies of glucocorticoid use. A second determinant of drug therapy is the evidence for fracture prevention in terms of spectrum (vertebral, nonvertebral and/or hip fractures), size and speed of effect. In the absence of head-to-head RCTs with fracture risk as the end point, however, the efficacy of antifracture drugs cannot be directly compared. Other determinants include the potential extraskeletal benefits and safety concerns of the drug, patient preferences and reimbursement issues.

Original languageEnglish
Pages (from-to)240-248
Number of pages9
JournalNature Clinical Practice Rheumatology
Volume4
Issue number5
Early online date8 Apr 2008
DOIs
Publication statusPublished - May 2008

Keywords

  • drug safety
  • drug treatment
  • fracture risk
  • glucocorticoid osteoporosis
  • postmenopausal osteoporosis
  • glucocorticoid-induced osteoperosis
  • prevalent vertebral fractures
  • randomized controlled-trial
  • bone-mineral density
  • parathyroid-hormone
  • postmenopausal osteoperosis
  • nonvertebral fractures
  • zoledronic fractures
  • antiresorptive agents
  • alendronate

Cite this

Geusens, P. P., Roux, C. H., Reid, D. M., Lems, W. F., Adami, S., Adachi, J. D., ... Hochberg, M. C. (2008). Drug Insight: choosing a drug treatment strategy for women with osteoporosis: an evidence-based clinical perspective. Nature Clinical Practice Rheumatology, 4(5), 240-248. https://doi.org/10.1038/ncprheum0773

Drug Insight: choosing a drug treatment strategy for women with osteoporosis : an evidence-based clinical perspective. / Geusens, Piet P.; Roux, Christian H.; Reid, David M.; Lems, Willem F.; Adami, Silvano; Adachi, Jonathan D.; Sambrook, Philip N.; Saag, Kenneth G.; Lane, Nancy E.; Hochberg, Marc C.

In: Nature Clinical Practice Rheumatology, Vol. 4, No. 5, 05.2008, p. 240-248.

Research output: Contribution to journalLiterature review

Geusens, PP, Roux, CH, Reid, DM, Lems, WF, Adami, S, Adachi, JD, Sambrook, PN, Saag, KG, Lane, NE & Hochberg, MC 2008, 'Drug Insight: choosing a drug treatment strategy for women with osteoporosis: an evidence-based clinical perspective', Nature Clinical Practice Rheumatology, vol. 4, no. 5, pp. 240-248. https://doi.org/10.1038/ncprheum0773
Geusens, Piet P. ; Roux, Christian H. ; Reid, David M. ; Lems, Willem F. ; Adami, Silvano ; Adachi, Jonathan D. ; Sambrook, Philip N. ; Saag, Kenneth G. ; Lane, Nancy E. ; Hochberg, Marc C. / Drug Insight: choosing a drug treatment strategy for women with osteoporosis : an evidence-based clinical perspective. In: Nature Clinical Practice Rheumatology. 2008 ; Vol. 4, No. 5. pp. 240-248.
@article{3b0377f6ac0842f6afa0c642c6ed7525,
title = "Drug Insight: choosing a drug treatment strategy for women with osteoporosis: an evidence-based clinical perspective",
abstract = "Many randomized controlled trials (RCTs) have investigated drug treatment for women at high risk of fracture, with a reduction in fracture risk as their end point. There has also been progress in identifying women at the highest risk of fractures. The most important clinical determinant contributing to the clinical decision of initiating and choosing drug therapy for fracture prevention is a woman's fracture risk, which, in RCTs, was determined by menopausal state, age, bone mineral density, fracture history, fall risks and glucocorticoid use. Women with secondary osteoporosis were excluded, except in studies of glucocorticoid use. A second determinant of drug therapy is the evidence for fracture prevention in terms of spectrum (vertebral, nonvertebral and/or hip fractures), size and speed of effect. In the absence of head-to-head RCTs with fracture risk as the end point, however, the efficacy of antifracture drugs cannot be directly compared. Other determinants include the potential extraskeletal benefits and safety concerns of the drug, patient preferences and reimbursement issues.",
keywords = "drug safety, drug treatment, fracture risk, glucocorticoid osteoporosis, postmenopausal osteoporosis, glucocorticoid-induced osteoperosis, prevalent vertebral fractures, randomized controlled-trial, bone-mineral density, parathyroid-hormone, postmenopausal osteoperosis, nonvertebral fractures, zoledronic fractures, antiresorptive agents, alendronate",
author = "Geusens, {Piet P.} and Roux, {Christian H.} and Reid, {David M.} and Lems, {Willem F.} and Silvano Adami and Adachi, {Jonathan D.} and Sambrook, {Philip N.} and Saag, {Kenneth G.} and Lane, {Nancy E.} and Hochberg, {Marc C.}",
year = "2008",
month = "5",
doi = "10.1038/ncprheum0773",
language = "English",
volume = "4",
pages = "240--248",
journal = "Nature Clinical Practice Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Drug Insight: choosing a drug treatment strategy for women with osteoporosis

T2 - an evidence-based clinical perspective

AU - Geusens, Piet P.

AU - Roux, Christian H.

AU - Reid, David M.

AU - Lems, Willem F.

AU - Adami, Silvano

AU - Adachi, Jonathan D.

AU - Sambrook, Philip N.

AU - Saag, Kenneth G.

AU - Lane, Nancy E.

AU - Hochberg, Marc C.

PY - 2008/5

Y1 - 2008/5

N2 - Many randomized controlled trials (RCTs) have investigated drug treatment for women at high risk of fracture, with a reduction in fracture risk as their end point. There has also been progress in identifying women at the highest risk of fractures. The most important clinical determinant contributing to the clinical decision of initiating and choosing drug therapy for fracture prevention is a woman's fracture risk, which, in RCTs, was determined by menopausal state, age, bone mineral density, fracture history, fall risks and glucocorticoid use. Women with secondary osteoporosis were excluded, except in studies of glucocorticoid use. A second determinant of drug therapy is the evidence for fracture prevention in terms of spectrum (vertebral, nonvertebral and/or hip fractures), size and speed of effect. In the absence of head-to-head RCTs with fracture risk as the end point, however, the efficacy of antifracture drugs cannot be directly compared. Other determinants include the potential extraskeletal benefits and safety concerns of the drug, patient preferences and reimbursement issues.

AB - Many randomized controlled trials (RCTs) have investigated drug treatment for women at high risk of fracture, with a reduction in fracture risk as their end point. There has also been progress in identifying women at the highest risk of fractures. The most important clinical determinant contributing to the clinical decision of initiating and choosing drug therapy for fracture prevention is a woman's fracture risk, which, in RCTs, was determined by menopausal state, age, bone mineral density, fracture history, fall risks and glucocorticoid use. Women with secondary osteoporosis were excluded, except in studies of glucocorticoid use. A second determinant of drug therapy is the evidence for fracture prevention in terms of spectrum (vertebral, nonvertebral and/or hip fractures), size and speed of effect. In the absence of head-to-head RCTs with fracture risk as the end point, however, the efficacy of antifracture drugs cannot be directly compared. Other determinants include the potential extraskeletal benefits and safety concerns of the drug, patient preferences and reimbursement issues.

KW - drug safety

KW - drug treatment

KW - fracture risk

KW - glucocorticoid osteoporosis

KW - postmenopausal osteoporosis

KW - glucocorticoid-induced osteoperosis

KW - prevalent vertebral fractures

KW - randomized controlled-trial

KW - bone-mineral density

KW - parathyroid-hormone

KW - postmenopausal osteoperosis

KW - nonvertebral fractures

KW - zoledronic fractures

KW - antiresorptive agents

KW - alendronate

U2 - 10.1038/ncprheum0773

DO - 10.1038/ncprheum0773

M3 - Literature review

VL - 4

SP - 240

EP - 248

JO - Nature Clinical Practice Rheumatology

JF - Nature Clinical Practice Rheumatology

SN - 1759-4790

IS - 5

ER -